OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Want to see OKUR full AI Analyst Report?
Total Valuation
OnKure Therapeutics has a market cap or net worth of $170.06M. The enterprise value is -$134.13M.
Market Cap$170.06M
Enterprise Value-$134.13M
Share Statistics
OnKure Therapeutics has 40,395,480 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,395,480
Owned by Insiders1.72%
Owned by Institutions63.84%
Financial Efficiency
OnKure Therapeutics’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -110.93%.
Return on Equity (ROE)-1.06
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-110.93%
Return on Capital Employed (ROCE)-1.12
Revenue Per Employee0.00
Profits Per Employee-1.29M
Employee Count46
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OnKure Therapeutics is ―. OnKure Therapeutics’s PEG ratio is -0.06.
PE Ratio―
PS Ratio0.00
PB Ratio0.70
Price to Fair Value0.70
Price to FCF-0.76
Price to Operating Cash Flow-1.13
PEG Ratio-0.06
Income Statement
In the last 12 months, OnKure Therapeutics had revenue of 0.00 and earned -59.52M in profits. Earnings per share was -4.40.
Revenue0.00
Gross Profit-830.00K
Operating Income-62.95M
Pretax Income-59.52M
Net Income-59.52M
EBITDA-62.12M
Earnings Per Share (EPS)-4.40
Cash Flow
In the last 12 months, operating cash flow was -50.76M and capital expenditures -33.00K, giving a free cash flow of -50.79M billion.
Operating Cash Flow-50.76M
Free Cash Flow-50.79M
Free Cash Flow per Share-1.26
Dividends & Yields
OnKure Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change86.28%
50-Day Moving Average4.24
200-Day Moving Average3.18
Relative Strength Index (RSI)54.61
Average Volume (3m)86.56K
Important Dates
OnKure Therapeutics upcoming earnings date is Aug 18, 2026, Before Open (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
OnKure Therapeutics as a current ratio of 10.28, with Debt / Equity ratio of 0.22%
Current Ratio10.28
Quick Ratio10.28
Debt to Market Cap0.01
Net Debt to EBITDA0.94
Interest Coverage Ratio0.00
Taxes
In the past 12 months, OnKure Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OnKure Therapeutics EV to EBITDA ratio is 0.31, with an EV/FCF ratio of 0.37.
EV to Sales0.00
EV to EBITDA0.31
EV to Free Cash Flow0.37
EV to Operating Cash Flow0.37
Balance Sheet
OnKure Therapeutics has $192.11M in cash and marketable securities with $409.00K in debt, giving a net cash position of $191.70M billion.
Cash & Marketable Securities$192.11M
Total Debt$409.00K
Net Cash$191.70M
Net Cash Per Share$4.75
Tangible Book Value Per Share$4.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for OnKure Therapeutics is $24.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$24.33
Price Target Upside386.67% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast25.85%